P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.648
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study

Lung Cancer Management
2019English

157P Second-Line Afatinib for Patients With Locally Advanced or Metastatic NSCLC Harbouring Common EGFR Mutations: A Phase IV Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-28 Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients With EGFR Mutation-Positive Advanced NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-47 Phase I/Ii Trial of Dasatinib and Osimertinib in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-34 Docetaxel Plus Ramucirumab With Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy